Medical Breakthroughs

Pear Therapeutics: FDA Clearance Isn’t Coverage. Why It Matters.

Listen to this article · 5 min listen

Pear Therapeutics did everything you’re supposed to do. They got three FDA clearances for their digital therapeutics, raised a boatload of cash, and even went public. And yet, they still ended up shutting down and selling off the pieces.

Regulatory Compliance and De Novo Classification

If you look at the FDA’s De Novo Classification record, you’ll see Pear Therapeutics’ name. They successfully used this pathway to get clearance for their novel, low-to-moderate-risk software as a medical device (SaMD) products, which is no small feat for devices without a clear predicate. Getting multiple FDA clearances proved their regulatory strategy was solid, and they had the peer-reviewed clinical data to back up their efficacy claims. On paper, they were golden.

Coverage Gate and External Review

Getting FDA clearance isn’t the same as getting paid. Market access and reimbursement are a completely separate hurdle. Just ask anyone trying to get coverage abroad, where external bodies like NICE in the UK have their own evidence standards that often demand far more data than what the FDA requires for initial clearance. Michael Pencina’s research offers a useful framework for this, helping to determine if the clinical endpoints you proved in a trial are actually relevant to a specific payer’s member population. It’s one thing to prove a device works. It’s another to prove it’s worth paying for.

Failure Cases: Clearance vs. Coverage

So Pear Therapeutics became the poster child for a specific type of failure: they aced the regulatory test but flunked the coverage and deployment one. It’s a different story than other big flameouts in health AI.

  • Theranos: They just failed on the science and regulatory side, full stop. The claims were bogus and they dodged oversight.
  • Olive AI: They ran into a different wall, struggling to prove their AI actually delivered a real return on investment or had enough clinical utility to justify its existence, which forced them into a major pivot.

The lesson here is that you can absolutely get through the FDA gate only to get stuck at the payer gate. Sure, a coverage team will check the FDA Clearance/Approval History first, but that’s just a single checkbox in a much longer due diligence list.

Coverage Team Due Diligence Questions

If you’re a lead for a health plan’s coverage and reimbursement team, you have to dig a lot deeper than just asking “Is it FDA-cleared?” Your real job starts after that. Here are the questions you should be asking any AI health vendor:

  • Does your tool actually solve a clinical problem we (the payer) care about and are measured on?
  • Show me the real-world evidence (RWE). I need to see strong data on cost-effectiveness and better patient outcomes, and not just in a perfect trial population but in diverse, messy, real-world groups. Examples of real-world evidence requirements for health technology assessment
  • How are we supposed to pay for this? Do you have CPT codes (Category I or III) or at least a believable plan to get them? AMA CPT code application process
  • From my perspective as the payer, what’s the long-term economic model here? How does this pencil out for me in year three or year five?
  • Algorithms drift. How do you monitor for that and keep performance from degrading over time? What’s your plan? FDA guidance on AI/ML medical device change control
  • Has anyone else (an independent body) vetted this? Has it gone through a health technology assessment (HTA) with an organization like NICE in the UK?
  • How does this plug into a real clinic’s day-to-day work? Can it be integrated without creating a massive new headache and training burden for providers?

The difference between regulatory clearance and payer coverage is everything. FDA clearance just confirms a product is safe and works as intended. It says nothing about its economic value or if it’s a smart financial decision for a health plan. You have to evaluate both of those gates on their own terms.

Frequently Asked Questions

Does FDA clearance guarantee market access or reimbursement for digital therapeutics?

No, regulatory clearance does not guarantee market access or reimbursement. Coverage decisions represent a separate, distinct gate that digital therapeutics must pass through. Pear Therapeutics is an example where regulatory compliance succeeded, but coverage failed.

What is the difference between regulatory clearance and coverage for health AI tools?

Regulatory clearance, such as FDA clearance, confirms a product’s safety and efficacy for its intended use. Coverage, however, determines its value proposition and financial viability for payers. These are two independent gates that require separate evaluation.

What types of evidence are important for coverage decisions beyond FDA clearance?

Beyond FDA clearance, robust real-world evidence (RWE) demonstrating cost-effectiveness and improved patient outcomes in diverse populations is crucial. External review bodies, like NICE (UK), establish evidence standards that often extend beyond the data required for FDA clearance.

What happened to Pear Therapeutics despite having multiple FDA clearances?

Despite achieving three FDA clearances for its digital therapeutics and raising substantial capital, Pear Therapeutics ultimately wound down operations. This occurred because, while they passed the regulatory gate, they failed at the coverage gate, meaning they couldn’t secure reimbursement.

Share
Was this article helpful?

Editorial Team

The Editorial Team at Trustworthy Health AI is a group of writers and editors who cover health, workplace wellness, and everyday care. They research each story and publish under a shared desk byline — experts in their fields, working as one team.